Page 7 - Pharma Sector

Chemists urge crackdown on instant online delivery of high-risk medicines

Chemists' body urges action against e-pharmacies, quick commerce apps for delivering high-risk drugs without checks, warning of rising misuse and youth addiction

Pfizer share price up 3% on rolling out this vaccine; key details inside

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.

Pharma Inc mulls offshore strategy as US tariff fears hit sentiment

Despite current exemptions, Indian pharma firms are preparing for potential US tariffs through offshore units, EU market focus, and sourcing diversification

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

The impact on innovator contract research, development and manufacturing organisations (CRDMOs) would be relatively lower

Ozempic maker's plight shows why managing markets matter for pharma giants

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting market sentiment in high-growth pharma bets

India launches formal rules to fix, streamline drug and device clearances

India has issued first official guidelines for expert panels to bring consistency, speed, and transparency to drug and device approvals amid a broader regulatory overhaul

Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show

Indoco Remedies announced that it has received a Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II.

Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Cipla buys 20% stake in iCaltech to broaden respiratory device portfolio

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore, expanding its presence in the respiratory diagnostics segment with a strategic investment in medical device development

Sun Pharma's psoriasis drug delivers positive results in arthritis trials

Phase 3 trials show ILUMYA improved PsA symptoms significantly, with no new safety concerns; results support potential regulatory submissions in the US and globally

Here's what brokerages expect from Dr Reddy's Labs ahead of Q1 show

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

CDSCO revises export NOC guidance document for new drug formulations

The CDSCO has updated its guidelines for issuing export NOCs for new drug formulations, including relaxations for FDCs, research-oriented drug batches, and SRA approvals

CDSCO extends COPP application deadline for pharma units to August 15

Pharma firms get time till August 15 to file COPP applications online via ONDLS as CDSCO addresses onboarding challenges and industry pleas

Lupin share price increases on rolling out eye medication; details here

Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.

Zeno Health expects 30% ecommerce revenue by FY26 through expansion

With a strong offline base in Mumbai and Pune, Zeno Health plans to expand into Tier II and III cities, starting with Bihar, driven by increasing demand

Electronics, pharma sectors corner 70% of PLI disbursements in FY25

Large-scale electronics manufacturing and pharmaceuticals cornered about 70 per cent of the total fiscal incentive disbursements in 2024-25 under the production-linked incentive (PLI) schemes, according to government data. The scheme was introduced in 2021 to support domestic manufacturing across 14 sectors with an outlay of Rs 1.97 lakh crore. In 2024-25, the government has disbursed a total of Rs 10,114 crore. PLI firms in the electronics sector received Rs 5,732 crore, while pharmaceutical drugs received Rs 2,328 crore, the data showed. In 2023-24, the disbursals stood at Rs 9,721 crore. The figures highlight the country's growing strength in these segments amid efforts to boost manufacturing and value-added exports. Besides these two, the other sectors that received these incentives in the last fiscal include bulk drugs (Rs 22 crore), Medical Devices (Rs 77 crore), Telecom (Rs 840 crore), Food Processing (Rs 448 crore), White Goods (Rs 210 crore), Automobiles (Rs 322 crore), .

Glenmark arm inks $700 million licensing deal with US-based AbbVie

IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million

Here's why Shilpa Medicare share price is buzzing in trade today; details

Shilpa Medicare shares rose today after the company secured GMP certification from Saudi Arabia's SFDA for its Unit VI facility in Dabaspet, Bengaluru.